iOnctura is a clinical-stage biopharmaceutical company combating neglected and hard-to-treat cancers with precision oral small molecules that target cancers in novel ways. The bold new treatments extend lives and improve healthspans, changing the outlook for patients and their families.
Products, services, technology
Roginolisib: the first allosteric modulator of PI3Kδ with an excellent clinical profile in PI, currently being investigated in multiple randomized PII studies.
Cambritaxestat: the only autotaxin inhibitor in clinical devleopment to treat cancer.
IOA-359: Targeting TGBb resistance.
Cooperation possibilities
We innovate, through pioneering scientific research, in collaboration with world renowned collaborators to develop selective therapies against targets of interest to us.
